Zamaglutenase

N/A

Report date: 2024/11/22 17:51:22

Base Information

Drug NameZamaglutenase
Drug Alias NameKumaMaxKuma-062PvP-001TAK-062
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionGliadin inhibitors
TargetsGliadin
Therapy Area/IndicationsCeliac DiseaseDigestive System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of WashingtonPvp Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd
Inactive CompaniesPvp Biologics IncMillennium Pharmaceuticals Inc
Active IndicationsCeliac Disease
Inactive IndicationsDigestive System Diseases

Other Information

ATC CodeN/A
Related LinksN/A